Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Proactively manage your pharmacy inventory
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Method of treating anxiety-related disorders using sertraline|
|Abstract:||A method of treating anxiety-related disorders comprising administering to a human in need of such treatment an amount of the compound (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine also known by the generic name sertraline, or a pharmaceutically acceptable salt thereof, effective in preventing or alleviating anxiety and the symptoms associated with anxiety-related disorders.|
|Inventor(s):||Doogan; Declan P. (Canterbury, GB2), Scappaticci; Karen A. (New York, NY), Hackett; Elizabeth (New York, NY)|
|Assignee:||Pfizer Inc. (New York, NY)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0429189||► subscribe|
|European Patent Office||1125581||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.